Follow Us:
Wednesday, August 10, 2022

Dr Reddy’s acquires GSK’s US facility

Dr Reddy's Laboratories has acquired GlaxoSmithKline's penicillin manufacturing facility.

Written by Agencies | New Delhi |
March 30, 2011 1:15:27 pm

Dr Reddy’s Laboratories today said it has acquired GlaxoSmithKline’s US penicillin manufacturing facility and the rights to the Augmentin (anti-biotic) and Amoxil brands in the United States for an undisclosed sum.

“GSK will retain the existing rights of these brands outside the United States,” Dr Reddy’s said in a filing to the Bombay Stock Exchange (BSE).

The acquisition of the oral pencillin manufacturing facility in Bristol and product portfolio was completed yesterday and is pursuant to the agreement signed by the companies on November 23,2010,it added.

The company,however,did not disclose the financial terms and conditions of the transaction.

Subscriber Only Stories
Sajjid Chinoy: ‘The rupee is a better-performing currency against t...Premium
Delhi Confidential: Amid Bihar drama, will Harivansh step down as Deputy ...Premium
Constant sparring, communication gap, poaching shadow: Why Nitish quit NDAPremium
Customs to airlines: Give details of foreign travellers for ‘risk analysis’Premium

Brands Augmentin and Amoxil,which are used for treating bacterial infections,are trademarks of GlaxoSmithKline.

Shares of Dr Reddy’s were being quoted at Rs 1,628.50 apiece in afternoon trade on the BSE today,up 2.21 per cent from their previous close.

📣 Join our Telegram channel (The Indian Express) for the latest news and updates

For all the latest News Archive News, download Indian Express App.

  • Newsguard
  • The Indian Express website has been rated GREEN for its credibility and trustworthiness by Newsguard, a global service that rates news sources for their journalistic standards.
  • Newsguard
First published on: 30-03-2011 at 01:15:27 pm

Featured Stories